Leucid Bio has dosed the first patient in its Phase 1 AERIAL trial evaluating LEU011, an innovative lateral CAR-T therapy targeting NKG2D stress ligands that are overexpressed in over 80% of human tumors.
Leucid Bio has received MHRA clinical trial authorization for LEU011, a novel lateral CAR-T therapy targeting NKG2D ligands expressed in over 80% of human tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.